BillionToOne raised $130 million in a Series D funding round led by Premji Invest to expand and scale their prenatal and oncology businesses.

Jan 13, 2025•11 months ago

Amount Raised

$130 Million

Round Type

series d

Menlo Park

Investors

Fifty YearsLibertus CapitalCivilization VenturesHummingbird VenturesBaillie GiffordAdam Street PartnersNeuberger BermanPremji Invest

Description

In June 2024, BillionToOne successfully raised $130 million in an oversubscribed Series D funding round. The funds will be utilized for the expansion and scaling of their prenatal and oncology businesses.

Company Information

Company

BillionToOne

Location

Menlo Park, California, United States

About

BillionToOne, headquartered in Menlo Park, California, is a precision diagnostics company with a mission to make molecular diagnostics more accurate, efficient, and accessible for all. The company's patent-pending QCT molecular counter platform is the only technology platform that can accurately count DNA molecules at the single-count level. BillionToOne's flagship product, UNITY, is the first and only noninvasive prenatal screening that tests fetal cell-free DNA for cystic fibrosis (CF), spinal muscular atrophy (SMA), and hemoglobinopathies through maternal blood. BillionToOne was co-founded by Oguzhan Atay, Ph.D. and David Tsao, Ph.D. For more information, visit www.billiontoone.com.

Related People

6 contacts

Funding Insights

Based on industry data

VC-backed spending patterns

VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers

Tech investment trends